riccardo masetti
Assistant Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Background Infections are the leading cause of non-relapse mortality in pediatric hematopoietic cell transplant (HCT) recipients. Up to 90% of bacteremias in these patients originate from gut microbiome organisms. However, selection for resistance genes, such as Extended-spectrum β-lactamase (ESBL), in these patient’s gut microbiomes remains poorly understood. Methods Stools were prospectively collected from pediatric HCT recipients at multiple centers (n=133 patients, five centers) on the day of HCT, the day of neutrophil engraftment, and 30 days post-HCT. Bacterial DNA was isolated and sent for shotgun metagenomic sequencing. Antibiotic resistance genes were identified using the MEGARes database. Associations between ESBL gene abundance changes and antibiotic exposure were examined using univariate and Inverse Probability of Treatment Weighting linear regression models with covariate balancing propensity scores. Results Pre-existing gut resistome disruption at the time of HCT showed a stronger correlation with ESBL gene expansion than post-transplant antibiotic exposure. Specifically, patients with greater baseline resistome distance from healthy children showed increased ESBL genes during the neutropenic period. Post-transplant β-lactam exposure (total or ESBL-cleavable) did not correlate with increases in ESBL genes in already-colonized patients. However, aminoglycosides and anaerobic active antibiotics were associated with acquisition of new ESBL organisms during the neutropenic period, while pre-existing microbiome disruption primarily drove selection of resistant bacteria already present. Conclusions These findings indicate that antibiotic stewardship before HCT, in addition to reducing the use of anaerobic active antibiotics during early transplant, may be necessary to prevent ESBL-related infections in pediatric transplant recipients. Lay Summary Infections are the leading cause of death after HCT, and recently the role of the gut microbiome in harboring dangerous bacteria has been highlighted. This study aims to understand multidrug resistant bacteria changes in the gut microbiome early after HCT.
Year:
2026
Juvenile myelomonocytic leukemia (JMML) is a myelodysplastic/myeloproliferative neoplasm of early childhood driven by RAS pathway mutations. Allogeneic hematopoietic stem cell transplantation (HSCT) is the therapy of choice for most patients. However, relapse rate is high, in patients with adverse features, frequently noted in PTPN11 -mutated JMML, or in patients without evidence of graft-versus-host disease (GvHD). Here we set out to understand the mechanisms associated with oncogenic PTPN11 immune escape. Analyzing primary PTPN11 -mutated JMML samples and MxCre;Ptpn11 D61Y/+ mice, we observed elevated expression of immune checkpoint molecules, including ectonucleotidases CD39 and CD73 - key mediators of the adenosine pathway - on monocytic and granulocytic leukemic cells. Stimulation with GM-CSF, a central mediator of JMML pathogenesis, induced ectonucleotidases expression on granulocytes and monocytes. In contrast, MEK inhibition downstream of Ptpn11 D61Y/ + reduced ectonucleotidases expression. Functionally, Ptpn11 D61Y/ + -mutated myeloid cells suppressed activation and proliferation of wild-type (WT) T lymphocytes, an effect recapitulated by adenosine and reversed by pharmacological CD39 inhibition with POM-1. In vivo , POM-1 treatment of MxCre ; Ptpn11 D61Y/+ mice presenting with myeloproliferation reduced spleen size and partially restored immune responsiveness. Moreover, POM-1 induced apoptosis in murine Ptpn11 D61Y/+ myeloid cells, highlighting a dual therapeutic benefit of CD39 inhibition in JMML. Together, these findings suggest that targeting the adenosine pathway may represent an immunomodulatory approach to enhance T cell-mediated control of JMML, particularly in the context of HSCT and relapse prevention.
Year:
2025
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. γδ T-ALL diagnosed in children under 3 years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer–promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High-throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by poly(ADP-ribose) polymerase inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric γδ T-ALL. Significance: Patients with acute lymphoblastic leukemia expressing the gamma delta T-cell receptor under 3 years old or measurable residual disease ≥1% at end of induction showed dismal outcomes and should be classified as having high-risk disease. The STAG2/LMO2 subtype was enriched in this very young age group. STAG2 inactivation may perturb chromatin conformation and cell differentiation and confer vulnerability to poly(ADP-ribose) polymerase inhibition.
Year:
2024
Objective To evaluate the safety of short-term use of inhaled salbutamol in children under 2 years of age with acute wheezing. Data sources Electronic databases (PubMed, Trip, MEDLINE) and the Cochrane Library were searched for studies published up to October 2022. Study selection The search was restricted to randomised controlled trials published in English regarding the safety of inhaled salbutamol in wheezing children under the age of 2. Data extraction and synthesis The literature search strategy yielded 3532 references. The meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Main outcome(s) and measure(s) The incidence of adverse reactions associated with inhaled salbutamol administration compared with placebo. Results A total of 24 records were included. In 7 studies involving 597 patients, inhaled salbutamol was compared with controls and no statistically significant difference in the incidence of adverse drug reactions was found between the two groups (OR 2.12, 95% CI 0.69 to 6.51; p=0.19). Salbutamol administration via nebulisation was associated with an increased incidence of adverse reactions (OR 6.76, 95% CI 2.01 to 22.71; p=0.002). None of the studies reported severe cardiac side effects that necessitated withdrawal from the study following salbutamol administration. Only one study reported a significant non-cardiac side effect (severe tremulousness) that necessitated withdrawal from therapy. Conclusions Inhaled salbutamol can be safely used in children under 2 years of age with acute wheeze with the administration via a metered-dose inhaler being potentially safer than a nebulised formulation. Neither of the formulations was associated with severe adverse effects.
Year:
2024
Collaborators (37)
Shondra Pruett-Miller
Associate Member
St. Jude Children's Research Hospital
Mariko Eguchi
Profesor
Ehime University Graduate School of Medicine
Chi Kong Li
Professor
The Chinese University of Hong Kong (CUHK)
Martin Schrappe
-
Kjeld Schmiegelow
-
Hanne Vibeke Hansen Marquart
Chief Physician; MD, PhD, Clinical Associate Professor
Copenhagen University Hospital
Allen Eng Juh Yeoh
National University of Singapore (NUS)
Atsushi Manabe
Professor
Hokkaido University
Gabriele Escherich
-
Valentino Conter
-
John Choi
The University of Alabama
Franco Locatelli
Full Professor of Pediatrics
Catholic University of the Sacred Heart
Elisa Margolis
Associate Professor
University of Utah
Steven Kornblau
Professor
The University of Texas MD Anderson Cancer Center
Junko Takita
教授 / Professor
Kyoto University
Szymon Skoczen
Associated Professor
Uniwersytet Jagiellonski Collegium Medicum
Kathryn Roberts
St. Jude Children's Research Hospital
David Teachey
Professor
Children's Hospital of Philadelphia
Daisuke Tomizawa
Head
National Center For Child Health and Development
Miriam Erlacher
Medical Director, Professor of Pediatrics
University Hospital Ulm
Cheng Cheng
Professor
St Jude Grade School of Biomedical Sciences
Janet Englund
Professor
-
Motohiro Kato
-
Takao Deguchi
Head of Division
National Center For Child Health and Development
Robert Zeiser
Director Div. of Tumor immunology/Professor
University Medical Center Freiburg
Ching-Hon Pui
Fahad Nasser Al-Rashid Chair of Leukemia Research
St. Jude Children's Research Hospital
Andrew Moore
Associate Professor
University of Queensland
Ilaria Iacobucci
Principal Scientist
St. Jude Children's Research Hospital
Joshua Wolf
St. Jude Children's Research Hospital
Edoardo Muratore
University of Bologna
Masatoshi Takagi
Tokyo Medical and Dental University
Zhaohui Gu
Assistant Professor
Beckman Research Institute, City of Hope
Paul G Thomas
Professor
Fred Hutch Cancer Center
Andishe Attarbaschi
Medical University of Vienna
Charles Mullighan
Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center
St. Jude Children's Research Hospital
Rishi Kotecha
Professor
Telethon Kids Institute
Eileen Klein
Professor
University of Washington
Make your next move.
Prepare your application
Review drafts before you send them.